[Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
In a prospective trial a combination of octreotide and tamoxifen was evaluated for its effect on tumour recurrence of R0-resected pancreatic carcinoma. Compared to the control group (n = 14), which was treated according to "best supportive care", the median survival times for the octreotide-tamoxifen group (n = 14) were 7 and 3.5 months respectively. In the octreotide-tamoxifen group patients suffered less from nausea, pain and fatigue (p < 0.05). Furthermore, there was a benefit of octreotide-tamoxifen therapy for global life quality.